The UK’s psychedelic healthcare industry
2023 is expected to be a pivotal year for psychedelic-assisted therapy, with multiple compounds entering the final stages of drug development.
The Medicines and Healthcare products Regulatory Agency (MHRA), which regulates medical treatments in the UK, has awarded Innovation Passports to psychedelic-assisted therapies to accelerate their time to market.
The UK is home to world-leading psychedelic research institutions and publicly traded companies, with direct access to London’s capital markets.
This lays the foundations for a flourishing domestic industry, with the PSYCH Symposium championing the emerging ecosystem.READ MORE